Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Painless ALA-PDT with pretreatment for moderate to severe acne vulgaris
ChiCTR2100046508Phase 4Recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of 5-aminolevulinic acid in acne vulgaris (2 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: reduction rate of lesions. Started Oct 2019; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2100046508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046508.